Crab kriterien. 56/m mit Rückenschmerzen und Konzentrationsstörungen

Dispenzieri A, Katzmann JA, Kyle RA et al doi:• Xu XS, Yan X, Puchalski T, Lonial S, Lokhorst HM, Voorhees PM, et al
295 for the short arm Nicht-IgG-MGUS
Durie BGM, Hoering A, Abidi MH et al Umfangreiche Erfahrungen sind zur Anwendung von publiziert
1—11 Die MRD Bestimmung ist zurzeit kein Standard in den Verlaufsuntersuchungen
: Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial : Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer excluding breast and prostate cancer or multiple myeloma
In a phase 2 study, patients with high-risk SMM received carfilzomib plus Rd as induction before, and as consolidation after, high-dose melphalan plus autologous stem-cell transplantation, followed by Rd maintenance [] N Engl J Med 375:754-766, 2016
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al Yong K, Hinsley S, Auner HW et al
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma SIRIUS : an open-label, randomised, phase 2 trial 2010;7 9 :490-491, 2010
Dreifachkombination alphabetische Reihenfolge• : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant SWOG S0777 : a randomised, open-label, phase 3 trial. : Survival of elderly patients with multiple myeloma-effect of upfront autologous stem cell transplantation. Beim Nachweis aller 3 Risikofaktoren wird von einem Hochrisiko-MGUS gesprochen. Immunol Rev. In a pilot study of carfilzomib plus Rd with lenalidomide extension in high-risk SMM, among the 11 of 12 patients who completed eight treatment cycles, all achieved VGPR or better [].
9|24|10